Results 31 to 40 of about 22,035 (254)

Preferred antiretroviral drugs for the next decade of scale up [PDF]

, 2012
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle, Cahn, Pedro, Calmy, Alexandra, Clayden, Polly, Ford, Nathan, Goemaere, Eric, Katlama, Christine, Levin, Andrew, Lynch, Sharonann, Raguin, Gilles, Vitoria, Marco   +10 more
core   +4 more sources

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro

International Journal of Molecular Sciences, 2022
The effective antiviral agents that treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed around the world. The 3C-like protease (3CLpro) of SARS-CoV-2 plays a pivotal role in virus replication; it also has become an ...
Ling Ma, Yongli Xie, Mei Zhu, Dong-Rong Yi, Jian-yuan Zhao, Saisai Guo, Yongxin Zhang, Jing Wang, Quanjie Li, Yucheng Wang, S. Cen   +10 more
semanticscholar   +1 more source

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. [PDF]

, 2014
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).MethodsING116070 is an ongoing, single-arm, open-label ...
Chen, Shuguang, extended ING116070 study team, Letendre, Scott L, Mills, Anthony M, Min, Sherene S, Piscitelli, Stephen C, Song, Ivy H, Tashima, Karen T, Thomas, Deborah A   +8 more
core   +7 more sources

A Case Report of Atypical Oral Angiolymphoid Hyperplasia With Eosinophilia (ALHE) Presenting as an Immune Reconstitution Inflammatory Syndrome in a Patient With HIV. [PDF]

Case Rep Otolaryngol
A 35‐year‐old man with uncontrolled human immunodeficiency virus (HIV) infection presented with a pharyngeal plaque‐like lesion after recommencing antiretroviral treatment (ART). Rapid localized growth of the lesion paralleled his rising CD4+ T‐cell count, suggesting immune reconstitution–mediated deterioration.
Haywood R, Post J.
europepmc   +2 more sources

An Efficient Synthesis of the Bicyclic Darunavir Side Chain Using Chemoenzymatic Catalysis

Organic Process Research & Development, 2022
Herein, we describe a chemoenzymatic synthesis of the bicyclic fragment of Darunavir. A ketoreductase was identified using metagenomic mining to catalyze a highly enantio- and diastereoselective dynamic kinetic resolution of a 𝛽-ketolactone.
Paul S. Riehl, Jesmine Lim, J. Finnigan, S. Charnock, T. Hyster   +4 more
semanticscholar   +1 more source

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus   +7 more
doaj   +1 more source

Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.

Journal of Antimicrobial Chemotherapy, 2022
BACKGROUND Pharmacokinetic data are lacking for progestin-releasing subdermal contraceptive implants when used with either rilpivirine- or darunavir/ritonavir-based ART.
S. Nakalema, C. Chappell, Michelle M. Pham, P. Byakika-Kibwika, J. Kaboggoza, S. Walimbwa, J. Musaazi, R. Nakijoba, L. Mbabazi, I. Kyohairwe, S. Nassiwa, Jeffrey Jeppson, Lee C. Winchester, M. Siccardi, C. Fletcher, K. Scarsi, M. Lamorde   +16 more
semanticscholar   +1 more source

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Current Issues in Molecular Biology, 2022
Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has ...
Juliana de C. Fenley, Patrícia P. de Barros, Paulo H. F. do Carmo, Maíra T. Garcia, Rodnei D. Rossoni, Juliana C. Junqueira   +5 more
doaj   +1 more source

Risk factors contributing to a low darunavir plasma concentration [PDF]

, 2017
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
Alffenaar, Jan Willem C., Bierman, Wouter F.W., Daskapan, Alper, Kosterink, Jos G.W., Stienstra, Ymkje, Touw, Daan J., van der Werf, Tjip S.   +6 more
core   +2 more sources

Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders

ACS Chemical Neuroscience, 2021
Human immunodeficiency virus (HIV) can independently replicate in the central nervous system (CNS) causing neurocognitive impairment even in subjects with suppressed plasma viral load. The antiretroviral drug darunavir (DRV) has been approved for therapy
T. Latronico, F. Rizzi, A. Panniello, V. Laquintana, I. Arduino, N. Denora, E. Fanizza, S. Milella, C. Mastroianni, M. Striccoli, M. Curri, G. M. Liuzzi, N. Depalo   +12 more
semanticscholar   +1 more source